克唑替尼治疗MET改变晚期透明细胞肉瘤的II期试验
EORTC 90101 CREATE II期试验评估克唑替尼250mg每日两次口服治疗晚期或转移性透明细胞肉瘤(CCSA)。28例可评估患者中26例MET+,确认部分缓解1例,ORR 3.8%(95%CI 0.1-19.6),DCR 69.2%,中位PFS 131天,中位OS 277天。MET+ CCSA的PFS与单药多柔比星一线治疗非选择转移性软组织肉瘤相似。
要点
- MET+ CCSA患者克唑替尼ORR 3.8%,DCR 69.2%,中位PFS 131天。
- 中位OS 277天,3/6/12/24月PFR分别为53.8%/26.9%/7.7%/7.7%。
- 常见治疗相关不良事件为恶心52.9%、乏力50.0%、呕吐35.3%。
核心结论
- MET+ CCSA患者克唑替尼的PFS与单药多柔比星一线治疗非选择转移性软组织肉瘤的结果相似。
- PFS与帕唑帕尼在既往治疗过的肉瘤患者中取得的结果相似。
研究设计与样本
- 欧洲癌症研究与治疗组织(EORTC)II期试验90101 CREATE,前瞻性研究克唑替尼在晚期或转移性CCSA患者中的疗效与安全性。
- 患者口服克唑替尼250 mg每日两次。
- 主要终点为客观缓解率(ORR),次要终点包括缓解持续时间、疾病控制率(DCR)、无进展生存期(PFS)、无进展率(PFR)、总生存期(OS)、OS率及安全性。
- 研究设计聚焦于经荧光原位杂交(FISH)证实EWSR1基因重排的MET+疾病。
- 43例同意患者中36例中心确认CCSA,28例符合条件、接受治疗并可评估;28例中26例为MET+。
主要发现
- MET+ CCSA患者中1例达到确认的部分缓解,17例疾病稳定,ORR 3.8%(95%CI 0.1-19.6)。
- MET+ CCSA进一步疗效终点:DCR 69.2%(48.2%-85.7%),中位PFS 131天(49-235),中位OS 277天(232-442)。
- 3、6、12和24个月PFR分别为53.8%(34.6-73.0)、26.9%(9.8-43.9)、7.7%(1.3-21.7)和7.7%(1.3-21.7)。
- 2例可评估MET-患者中,1例疾病稳定,1例疾病进展。
- 最常见治疗相关不良事件:恶心18/34(52.9%)、乏力17/34(50.0%)、呕吐12/34(35.3%)、腹泻11/34(32.4%)、便秘9/34(26.5%)、视力模糊7/34(20.6%)。
临床怎么用
- 对于经FISH证实EWSR1重排的MET+晚期CCSA患者,可考虑克唑替尼250 mg每日两次口服治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic CCSA. PATIENTS AND METHODS: Patients with CCSA received oral crizotinib 250 mg twice daily. Primary end point was objective response rate (ORR), secondary end points included duration of response, disease control rate (DCR), progression-free survival (PFS), progression-free rate (PFR), overall survival (OS), OS rate and safety. The study design focused on MET+ disease with documented rearrangement of the EWSR1 gene by fluorescence in situ hybridization. RESULTS: Among 43 consenting patients with the local diagnosis of CCSA, 36 had centrally confirmed CCSA, 28 of whom were eligible, treated and assessable. Twenty-six out of the 28 patients had MET+ disease, of whom one achieved a confirmed partial response and 17 had stable disease (SD) (ORR 3.8%, 95% confidence interval: 0.1-19.6). Further efficacy end points in MET+ CCSA were DCR: 69.2% (48.2% to 85.7%), median PFS: 131 days (49-235), median OS: 277 days (232-442). The 3-, 6-, 12- and 24-month PFR was 53.8% (34.6-73.0), 26.9% (9.8-43.9), 7.7% (1.3-21.7) and 7.7% (1.3-21.7), respectively. Among two assessable MET- patients, one had stable disease and one had progression. The most common treatment-related adverse events were nausea [18/34 (52.9%)], fatigue [17/34 (50.0%)], vomiting [12/34 (35.3%)], diarrhoea [11/34 (32.4%)], constipation [9/34 (26.5%)] and blurred vision [7/34 (20.6%)]. CONCLUSIONS: The PFS with crizotinib in MET+ CCSA is similar to results achieved first-line in non-selected metastatic soft tissue sarcomas with single-agent doxorubicin. The PFS is similar to results achieved with pazopanib in previously treated sarcoma patients. CLINICAL TRIAL NUMBER: EORTC 90101, EudraCT number 2011-001988-52, NCT01524926.
引用
- Schöffski P, Wozniak A, Stacchiotti S, et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. Ann Oncol. 2017. PMID: 28950372. doi:10.1093/annonc/mdx527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。